• (S)-(+)-Dimethindene maleate: Practical Guide for M2 Antagon

  2026-06-16

  (S)-(+)-Dimethindene maleate offers a selective approach to modulating muscarinic acetylcholine receptor subtype M2 and histamine H1 receptors, supporting precise research into autonomic regulation, cardiovascular, and respiratory physiology. This compound is best used in in vitro and ex vivo assay workflows for receptor selectivity profiling; it is not recommended for diagnostic or therapeutic applications.

• HBsAg Modulates TBK1 to Suppress Interferon and Induce Autop

  2026-06-16

  This study reveals how hepatitis B surface antigen (HBsAg) manipulates TANK-binding kinase 1 (TBK1) to suppress type I interferon production and induce early autophagy in host cells. By delineating the disruption of innate immune signaling and the promotion of incomplete autophagy, the research provides new mechanistic insight into HBV persistence and immune evasion.

• MK-4827 (Niraparib): Potent PARP-1/-2 Inhibition in Cancer R

  2026-06-15

  MK-4827 (Niraparib) is a potent, selective PARP-1/-2 inhibitor with nanomolar activity, widely used in BRCA-mutant cancer research. It impairs DNA repair, sensitizes tumor cells, and shows robust preclinical efficacy with favorable tolerability. This article consolidates mechanistic, benchmark, and workflow data for optimal research deployment.

• 3-(1-methylpyrrolidin-2-yl)pyridine (N2703): Biosynthetic In

  2026-06-15

  Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) advances molecular mechanism research by leveraging recent biosynthetic pathway discoveries. This in-depth analysis uniquely connects N2703’s molecular properties with practical assay design and interpretation.

• Forsythoside E: Reliable PKM2 Inhibition for Macrophage Assa

  2026-06-14

  This article guides biomedical researchers through real-world challenges in cell viability and immunometabolic assays, demonstrating how Forsythoside E (SKU N2883) addresses reproducibility, mechanistic specificity, and workflow compatibility. Evidence-supported recommendations and protocol parameters help labs achieve reliable macrophage polarization and PKM2 inhibition outcomes.

• Caspase-8 Fluorometric Assay Kit: Precision in Apoptosis Ass

  2026-06-13

  The Caspase-8 Fluorometric Assay Kit empowers apoptosis and cell death research with a rapid, one-step workflow and exceptional specificity for cysteine-dependent aspartate-directed protease activity. Its compatibility with combination therapy studies and advanced protocol customization make it a standout tool for translational cancer and neurodegenerative disease models.

• Practical Use of (S)-(+)-Dimethindene Maleate in M2 Antagoni

  2026-06-12

  (S)-(+)-Dimethindene maleate offers researchers a selective, high-purity M2 muscarinic receptor antagonist with dual H1 histamine blocking properties, enabling precise experimental modulation in studies of autonomic regulation, cardiovascular physiology, and respiratory function. It is not suitable for diagnostic or clinical use, and success depends on careful attention to solubility, storage, and workflow parameters.

• Distinct Mechanisms of AKT Inhibitors: Insights for DNA Dama

  2026-06-12

  This article analyzes a systematic evaluation of AKT inhibitors, revealing how ATP-competitive and allosteric agents exert distinct effects on AKT signaling, isoform selectivity, and resistance profiles. The study’s mechanistic findings inform the design of targeted cancer therapeutic strategies and highlight implications for integrating DNA damage response inhibitors into research.

• Taxus chinensis Fruit Extract Inhibits Neuroinflammation via

  2026-06-11

  The referenced study demonstrates that Taxus chinensis fruit extract (TCFE) significantly attenuates aging behaviors and neuroinflammation in a D-galactose-induced mouse model by inhibiting microglial activation through the TLR4/NF-κB/NLRP3 pathway. These findings elucidate both a mechanistic and translational foundation for using TCF-derived compounds in neuroinflammation and aging research.

• EZ Cap™ Firefly Luciferase mRNA: Redefining Bioluminescent R

  2026-06-11

  Explore how EZ Cap™ Firefly Luciferase mRNA leverages Cap 1 structure and advanced stability features to transform mRNA delivery and bioluminescent reporter assays. This article offers new scientific insights and practical guidance beyond standard protocols.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-10

  The reference dissertation introduces a systematic comparison of in vitro methods for evaluating anti-cancer drug responses, distinguishing between relative and fractional viability as separate but complementary metrics. These advances clarify how drugs like novel PARP inhibitors affect proliferation and cell death, supporting more precise preclinical modeling and translational study design.

• DMXAA (Vadimezan): Advanced Protocols for Tumor Vascular Dis

  2026-06-10

  DMXAA (Vadimezan) is redefining cancer biology research as a precise vascular disrupting agent and apoptosis inducer in tumor endothelial cells. This guide delivers stepwise protocols, troubleshooting, and actionable insights to help researchers optimize DMXAA-based workflows in angiogenesis and non-small cell lung cancer models.

• ATRA Overcomes Platinum-Induced PARPi Resistance in Ovarian

  2026-06-09

  This study demonstrates that all-trans retinoic acid (ATRA) can resensitize epithelial ovarian cancer (EOC) cells to PARP inhibition following cisplatin exposure. By targeting key resistance pathways, ATRA in combination with PARP inhibitors offers a promising strategy to improve outcomes in recurrent, chemoresistant EOC.

• Central Pathways in Opioid-Induced Mechanical Hypersensitivi

  2026-06-09

  Yin et al. (2024) elucidate a distinct brain-to-spinal pathway that governs mechanical opioid-induced hypersensitivity and analgesic tolerance, overturning prior assumptions about peripheral mediation. These findings provide a mechanistic framework for targeting opioid side effects in chronic pain research.

• Topotecan as a Topoisomerase I Inhibitor: Clinical and Resea

  2026-06-08

  This review synthesizes the pharmacological innovation of topotecan as a water-soluble, semisynthetic topoisomerase I inhibitor. It highlights its unique mechanism of inducing DNA damage and apoptosis in cancer cells, discusses clinical evidence for its antitumor activity, and situates its findings in relation to established alkylating agents such as cyclophosphamide.

11482 records 1/766 page Next 12345 下5页 Last page